MYX – Macquarie rates the stock as Neutral

Reported operating earnings (EBITDA) were below Macquarie’s estimates. Generics revenue fell by -33% with underlying gross margins down -11%. Meanwhile, growth in specialty brands moderated.

Macquarie is looking for increased uptake and additional revenue going forward from Lexette and Tolsura. Neutral maintained. Target is reduced to $0.41 from $0.57.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $0.41.Current Price is $0.38. Difference: $0.03 – (brackets indicate current price is over target). If MYX meets the Macquarie target it will return approximately 7% (excluding dividends, fees and charges – negative figures indicate an expected loss).

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →